Maurie Markman, MD

Articles

Is Therapeutic Value a New Name for Medical Paternalism?

October 14th 2022

What is noteworthy is the process whereby this patient employs both objective data and his personal beliefs to declare what he values.

Interventions Are Needed to Bridge Gaps Between Real-World and Clinical Trial Populations

September 29th 2022

Outcomes from randomized phase 3 cancer trials are the foundation for regulatory approvals of novel antineoplastic therapeutics and, when available, treatment guidelines.

Benchmarks in Clinical Trial Design Require Closer Examination by Oncologists

September 14th 2022

Maurie Markman, MD, elaborates on the need to take a closer look at the benchmarks used in clinical trial designs in oncology.

Implementation Research Takes On an Increasingly Essential Role in Oncology

August 29th 2022

The publication of the objectively meaningful outcomes in high-impact peer-reviewed medical journals does not necessarily result in the observations being implemented into routine clinical care.

Unique Aspects of Maintenance Therapy in Oncology Require Careful Consideration

August 14th 2022

Maurie Markman, MD, discusses maintenance therapy and how it differs from other strategies in cancer care.

A Revolution Is Pending for Real-World Data Use in Cancer Care

August 1st 2022

In the opinion of this commentator, one of the more exciting developments in clinical investigation over the past several years is the increasing recognition of the importance of real-world data and its role for physicians, regulators, policy makers, patients, and society.

Is It Time to Formally Recognize That PFS Is More Than a "Surrogate" End Point?

July 18th 2022

Peer-reviewed articles continue to challenge the recognition of progression-free survival as an acceptable primary end point in randomized cancer trials or insist on labeling this objectively measured outcome as nothing more than a potential surrogate for effects representing actual clinically meaningful results.

Metrics in Clinical Medicine and Clinical Trials Should Look Beyond the P Value

June 30th 2022

From evaluating clinical outcomes to determining payment for services, measurements are important in health care.

Markman Highlights Key Areas of Investigation in Oncology

June 19th 2022

Maurie Markman, MD, offers expert insights on the hurdles facing community oncologists, the uptake of biomarkers in the clinic, and an overview of what to look forward to in his area of expertise: gynecologic oncology.

Peer-Reviewed Data Present an Essential But Problematic Component of Oncology Research

May 31st 2022

There are serious concerns about textbook descriptions of peer review, specifically within the realm of clinical research, which pose a threat to both the objectivity of the field of investigative medicine and, perhaps most importantly, to the public’s support of clinical science.

The Saga of Regional Therapy in the Treatment of Ovarian Cancer

May 17th 2022

Despite numerous well-designed and conducted randomized trials, a definitive answer to the role of specific disease management remains unclear, particularly in the discussions of the optimal role for the regional delivery of cytotoxic chemotherapy in the treatment of patients with ovarian cancer.

We Must Improve Communication With the Public

May 2nd 2022

Maurie Markman, MD, discusses the need for oncologists to improve communication with the public and patients.

Pragmatic Clinical Trials Can Play a Key Role in Oncology

April 20th 2022

Pragmatic clinical trials “inform a clinical or policy decision by providing evidence for adoption of the intervention into real-world clinical practice.”

Unexpected but Potentially Actionable Cancer Clinical Trial Results: What Happens Next?

April 4th 2022

Maurie Markman, MD, discusses the obstacles between implementing clinical trial data into practice.

The Language of Science Is No Longer Just for Clinicians

March 22nd 2022

Maurie Markman, MD, discusses the expansion and overlap of the language of science within different medical disciplines and the general public.

Cancer Efforts Face Setback as Ongoing Challenges to Scientific Authority Continue

March 3rd 2022

Maurie Markman, MD, discusses the obstacles presented to cancer efforts as a result of challenges to scientific authority during the COVID-19 pandemic.

Serious Concerns Cloud Potential Benefit of Liquid Biopsy in Cancer Screening

February 3rd 2022

Maurie Markman, MD, explains the concerns surrounding liquid biopsies in cancer screening, and why regulatory agencies should be cautious and not approve any proposed molecularly based cancer diagnostic screening strategy until the tool is shown to effect cancer-specific survival compared with a control population not undergoing such testing.

The Clinical Utility of Surrogate End Points Sparks Debate in Oncology

January 20th 2022

Maurie Markman, MD, discusses the debate between surrogate end points of overall survival and progression-free survival in clinical trials within oncology.

Implications of FDA Approval of Alzheimer Drug May Extend to Novel Anticancer Therapies

January 10th 2022

It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.

The Future of Cancer Care Depends on Trust in the Scientific Community

January 4th 2022

Maurie Markman, MD, shares how evidence strongly supports that approaches to cancer prevention have little chance of success unless those being targeted are willing to listen to, and ultimately trust, the recommendations being made by members of the scientific community.